TREXLIEVA 50 mg contains Methotrexate, an antimetabolite and antifolate chemotherapeutic agent. It inhibits dihydrofolate reductase (DHFR), leading to reduced DNA synthesis and cell replication, particularly in rapidly dividing cells. It is widely used in oncology, autoimmune diseases, and medical oncology protocols.

Methotrexate is used in:

Oncology:

1. Acute Lymphoblastic Leukemia (ALL)

2. Non-Hodgkin’s Lymphoma

3. Osteosarcoma (high-dose therapy)

4. Choriocarcinoma & Gestational Trophoblastic Disease

5. Breast Cancer

6. Head & Neck Cancers

Common side effects:

•  Myelosuppression

•  Nausea, vomiting

•  Mucositis, stomatitis

•  Fatigue

Serious side effects:

•  Hepatotoxicity

•  Nephrotoxicity (especially at high doses)

•  Pulmonary toxicity

•  Severe infections

Monitor CBC, liver function, renal function, and methotrexate serum levels in high-dose therapy.

Dosage varies widely depending on indication.

Typical dosing:

•  Low dose:
    – 7.5–25 mg once weekly (non-oncology uses)

•  Oncology regimens:
    – 50 mg/m² to high-dose (>1 g/m²) IV/IM as per protocol


NOTE: This medicine should be taken only under a doctor’s supervision.

50 mg strength is commonly used for low–moderate dose regimens and dose adjustments.